Oasmia
Vallongatan 1
Uppsala
SE-752 28
Tel: 46-18-50-54-40
Fax: 46-18-51-08-73
Website: http://www.oasmia.com/
Email: info@oasmia.com
41 articles about Oasmia
-
Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB
3/1/2021
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM), an innovation-focused specialty pharmaceutical company, for Cantrixil (TRX-E-002-1)
-
ROSEN, A HIGHLY RANKED LAW FIRM, Reminds Oasmia Pharmaceutical AB Investors of September 27th Deadline in First Filed Securities Class Action Commenced by the Firm
8/31/2019
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Oasmia Pharmaceutical AB from October 23, 2015 through July 9, 2019, inclusive of the important September 27, 2019 lead plaintiff deadline in the securities class action commenced by the firm.
-
SHAREHOLDER ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: September 27, 2019
8/1/2019
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Oasmia Pharmaceutical AB and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Oasmia securities between October 23, 2015 through July 9, 2019, both dates inclusive.
-
Oasmia Pharma Receives Marketing Approval for Paclical in Kazakhstan
12/11/2017
Paclical will be sold through Hetero Group and is planned to be launched during the first half of 2018.
-
Oasmia Receives Market Approval For Its Anti-Cancer Drug Doxophos In Russia
8/10/2017
-
The Oasmia Annual Report Is Now Published
7/7/2017
-
Issuance Of Warrants In Oasmia
6/21/2017
-
Oasmia Reports Positive Results From Study On Weekly Administration Of Apealea (Paclical)
12/22/2016
-
Oasmia In Discussions Concerning Acquisition Of Novel Cancer Project
10/24/2016
-
Oasmia Enters Into Collaboration Agreement For Novel Cancer Project
10/24/2016
-
Sales Focus For Oasmia
6/8/2016
-
Oasmia Touts Positive Paclical/Apealea Phase III Data; NDA Being Readied for U.S.
4/27/2016
-
Oasmia Reports Positive Clinical Study Results For Proprietary XR17 Nanotechnology
4/5/2016
-
Oasmia Announces Enrollment Of First Patient In Clinical Study With Docecal, A Novel Formulation Of Docetaxel
3/30/2016
-
Oasmia: Interviewed By Nyhetsbyrån Direkt
3/24/2016
-
Oasmia Release: OASM Advances Global Commercialization Efforts For All Products
2/25/2016
-
Oasmia Has Submitted A Marketing Authorization Application To The European Medicines Agency For Its Lead Cancer Product Apealea (Paclical)
2/8/2016
-
Oasmia Makes Key Hires; Strengthens Organizational Structure Entering Commercial Phase
2/3/2016
-
Oasmia Receives Order Of $7.5 Million In End-User Value For The Russian Market
10/30/2015
-
Oasmia Executes First Commercial Order Of Paclical For The Russian Market
10/28/2015